Stocksigma LogoStocksigma Logo

Mahamaya Lifesciences Outlines Strategic Growth, Financial Expansion, and Dahej Facility Roadmap

Mahamaya Lifesciences reported robust FY'25–'26 performance, with revenue up 24.5% YoY to Rs. 328.87 crore, EBITDA rising 32.6% YoY to Rs

Mahamaya Lifesciences Outlines Strategic Growth, Financial Expansion, and Dahej Facility Roadmap

Mahamaya Lifesciences Ltd · Others (Uncategorized) · 09 Oct 2026, 11:15 pm

Mahamaya Lifesciences Outlines Strategic Growth, Financial Expansion, and Dahej Facility Roadmap Mahamaya Lifesciences reported robust FY'25–'26 performance, with revenue up 24.5% YoY to Rs. 328.87 crore, EBITDA rising 32.6% YoY to Rs. 34.26 crore, and PAT surging 29.0% YoY to Rs. 16.52 crore. Net debt-to-equity improved to 0.74x from 1.18x. The company is deploying IPO proceeds toward backward integration at Dahej, Gujarat, targeting formulation expansion and pilot operations by Dec'26, followed by commercial technical production in 2027. Strategic focus includes expanding proprietary branded products, high-margin bio-fermented solutions, and overseas registrations across LatAm, Middle East, and Africa.

Original exchange filing (PDF)

More announcements from Mahamaya Lifesciences Ltd

All Mahamaya Lifesciences Ltd announcements